- Home
- FBRX vs BDTX Comparison
FBRX vs BDTX Comparison
Compare FBRX & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- BDTX
- Stock Information
- Founded
- FBRX N/A
- BDTX 2014
- Country
- FBRX United States
- BDTX United States
- Employees
- FBRX N/A
- BDTX N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBRX Health Care
- BDTX Health Care
- Exchange
- FBRX Nasdaq
- BDTX Nasdaq
- Market Cap
- FBRX 154.5M
- BDTX 181.4M
- IPO Year
- FBRX N/A
- BDTX 2020
- Fundamental
- Price
- FBRX $11.60
- BDTX $2.97
- Analyst Decision
- FBRX Strong Buy
- BDTX Strong Buy
- Analyst Count
- FBRX 2
- BDTX 6
- Target Price
- FBRX $61.00
- BDTX $14.83
- AVG Volume (30 Days)
- FBRX 73.6K
- BDTX 1.3M
- Earning Date
- FBRX 08-13-2025
- BDTX 08-05-2025
- Dividend Yield
- FBRX N/A
- BDTX N/A
- EPS Growth
- FBRX N/A
- BDTX N/A
- EPS
- FBRX N/A
- BDTX 0.09
- Revenue
- FBRX N/A
- BDTX $70,000,000.00
- Revenue This Year
- FBRX N/A
- BDTX N/A
- Revenue Next Year
- FBRX N/A
- BDTX N/A
- P/E Ratio
- FBRX N/A
- BDTX $33.71
- Revenue Growth
- FBRX N/A
- BDTX N/A
- 52 Week Low
- FBRX $4.11
- BDTX $1.20
- 52 Week High
- FBRX $28.68
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- FBRX 53.91
- BDTX 59.01
- Support Level
- FBRX $10.02
- BDTX $3.02
- Resistance Level
- FBRX $10.99
- BDTX $3.28
- Average True Range (ATR)
- FBRX 0.86
- BDTX 0.19
- MACD
- FBRX -0.06
- BDTX 0.00
- Stochastic Oscillator
- FBRX 60.78
- BDTX 59.41
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.